News | January 06, 2023
PMBI launches Jan Aushadhi Chyawanprash Special
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
Having a healthy gut is key as it permits the body to build a stronger immune system
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
The advanced laboratory spread over 2,200 Square feet has multiple laboratory divisions including Hematology, Biochemistry, Clinical pathology, Serology and Microbiology
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of US $509 million in the US (IQVIA MAT October 2022)
Subscribe To Our Newsletter & Stay Updated
